Concomitant LAAC/AF Ablation (Watchman FLX Pro)
- Conditions
- PFA Ablation and LAAC Procedures
- Registration Number
- NCT07041125
- Brief Summary
This sub-study is a prospective/retrospective, non-randomized, observational, comparative cohorts study, embedded in and expanding on the infrastructure of a real-world AF ablation registry DISRUPT-AF (NCT06335082).
- Detailed Description
The prospective arm of the sub-study is intended to enroll 120 subjects indicated for PFA and Watchman in up to 20 US sites within the framework of the DISRUPT-AF registry. Subjects will be screened for eligibility to participate in concomitant PFA ablation for AF and LAAC by Watchman FLX Pro device in a single procedure. Both PVI and LAAC procedures are performed per SOC. In general, percutaneous catheterization will be initially established using FARADRIVE™ steerable sheath for ablation treatment of AF using the FARAWAVE Catheter per instruction for use (IFU) of the device and operator's standard practice. AF ablation will include PVI. Additional right or left atrial ablations are per investigators' discretions. After AF ablation, the FARAWAVE Catheter will be withdrawn. The FARADRIVE™ steerable sheath will be replaced with Watchman FLX deployment sheath. Deployment of Watchman FLX Pro device to LAA to achieve LAAC will follow the standard practice of the care and IFU of the device. Patients will be followed up at 45-90 days for LAAC implant assessment and at 3, 6, and 12 months for arrhythmia recurrence assessment
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 120
All inclusion criteria of the main DISRUPT-AF registry will apply. In addition, patients included in this sub study must meet the additional inclusion criteria below:
- Patients who are determined by physicians to be eligible for LAAC
- Patients whose LAAC with Watchman FLX Pro procedures are performed concomitant following AF ablation procedure
- Willing and able to provide additional informed consent to the sub-study (unless waiver of consent is obtained)
All exclusion criteria of the main DISRUPT-AF registry will apply. In addition, patients included in this sub study have the additional exclusion criteria below:
-Patients who are participating in other DISRUPT-AF sub-studies
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The occurrence of events between the time of implant and within 7 days following the procedure 12 months AF ablation safety will be compared between the concomitant procedures and standalone AF ablation cohort. and LAAC procedure safety will be compared between the concomitant procedures and standalone LAAC cohort.
- Secondary Outcome Measures
Name Time Method LAAC success and late-onset safety 12 months 45-90 days leaks around LAAC device, 45-90 days device-related thrombus and
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (11)
Arrhythmia Institute at Grandview
🇺🇸Birmingham, Alabama, United States
Norton Heart & Vascular Institute
🇺🇸Louisville, Kentucky, United States
St, Mark's Hospital
🇺🇸Salt Lake City, Utah, United States
Chippenham Hospital)
🇺🇸Richmond, Virginia, United States
Arrhythmia Center of South Florida
🇺🇸Delray Beach, Florida, United States
Ascension St. Vincent's Jacksonville
🇺🇸Jacksonville, Florida, United States
HCA Research Institute- Mercy Hospital
🇺🇸Miami, Florida, United States
Ascension St Vincent -Indianapolis Ascension Health
🇺🇸Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Allegheny General Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Scroll for more (1 remaining)Arrhythmia Institute at Grandview🇺🇸Birmingham, Alabama, United StatesKaren Burns, RNContactkaren.burns@grandviewhealth.comSusan Thorington, RNContactsusan.thorington@grandviewhealth.comAnil Rajendra, MDPrincipal Investigator
